Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences Inc. (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through its proprietary Phospholipid Drug Conjugate™ platform. This centralized news resource provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access real-time information about CLRB’s radiopharmaceutical pipeline, including lead candidate iopofosine I 131 for hematologic malignancies and emerging programs targeting solid tumors. Our news collection covers critical updates ranging from trial results to manufacturing advancements, all curated to support informed decision-making.
Key content areas include clinical trial progress, FDA designations, scientific presentations, and corporate collaborations. The platform serves as a reliable source for tracking the company’s mission to improve cancer treatment precision through its novel drug delivery technology.
Bookmark this page for continuous access to verified updates about Cellectar’s innovative oncology programs. Check regularly for new developments in targeted radiopharmaceuticals and PDC platform applications across therapeutic areas.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported financial results for the year ended December 31, 2022, highlighting a net loss of $28.6 million, or $4.05 per share, compared to a net loss of $24.1 million, or $4.35 per share, in 2021. The company held cash and equivalents of $19.9 million, down from $35.7 million in 2021, with a net cash usage of approximately $25.2 million. R&D expenses rose to $19.2 million from $17.6 million, while G&A expenses increased to $9.5 million from $6.5 million. Notably, the company presented positive clinical data from ongoing trials and announced key leadership appointments, strengthening its commercial strategy in hematology and oncology.
FAQ
What is the current stock price of Cellectar Biosciences (CLRB)?
What is the market cap of Cellectar Biosciences (CLRB)?
